LONDON (Reuters) - A closely watched AstraZeneca drug did not extend lives of patients with the rare cancer mesothelioma when given on its own, but the drugmaker said it still believed the medicine had a role to play in combination treatments. (Source: Reuters: Health)
from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=168209005&cid=c_409_26_f&fid=23271&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Freuters%2FhealthNews%2F%7E3%2FfqYfnCs4MAQ%2Fstory01.htm
Closely watched AstraZeneca cancer drug fails in mesothelioma
ad
Enregistrer un commentaire